Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Regor Pharmaceuticals Inc.
Regor Pharmaceuticals Inc.
Seagen Inc.
Eli Lilly and Company
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
Genentech, Inc.
National Cancer Institute (NCI)
Eli Lilly and Company
OncoC4, Inc.
Kortuc, Inc.
KaliVir Immunotherapeutics
Arcus Biosciences, Inc.
Radiopharm Theranostics, Ltd
Sotio Biotech Inc.
SystImmune Inc.
Rondo Therapeutics
M.D. Anderson Cancer Center
Orano Med LLC
Atavistik Bio, Inc
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Alterome Therapeutics, Inc.
Sutro Biopharma, Inc.
ViroMissile, Inc.
AbbVie
Tizona Therapeutics, Inc
Normunity AccelCo, Inc.
Institute of Cancer Research, United Kingdom
Jonsson Comprehensive Cancer Center
MacroGenics
UNC Lineberger Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
SystImmune Inc.
Pheon Therapeutics
Xinqiao Hospital of Chongqing
Tongji Hospital
Eli Lilly and Company
Fusion Pharmaceuticals Inc.
Innate Pharma
Dren Bio
Memorial Sloan Kettering Cancer Center
OncoNano Medicine, Inc.
City of Hope Medical Center
Risen (Suzhou) Pharma Tech Co., Ltd.
Shanghai Junshi Bioscience Co., Ltd.
Therorna
HiFiBiO Therapeutics
TScan Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)